Current Report Filing (8-k)
June 17 2019 - 8:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
June 16, 2019
VBI
VACCINES INC.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
|
|
001-37769
|
|
N/A
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
|
|
02142
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
Common
Shares, no par value per share
|
|
VBIV
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
7.01 Regulation FD Disclosure.
VBI
Vaccines Inc. (the “Company”) intends to use a slide presentation, which is attached hereto as Exhibit 99.1, to accompany
a previously announced conference call and webcast to be held on June 17, 2019, at 8:00 a.m. Eastern Time, providing top-line
results from PROTECT study, a pivotal Phase 3 study of Sci-B-Vac®. The Company undertakes no obligation to update, supplement
or amend the materials attached hereto as Exhibit 99.1.
In
accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including
Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set
forth by reference in such a filing.
Item
8.01 Other Events.
On
June 16, 2019, the Company issued a press release announcing the conference call and webcast to be held on June 17, 2019,
at 8:00 a.m. Eastern Time. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
On
June 17, 2019, the Company issued a press release announcing positive top-line results from the PROTECT study. A copy of the press
release is attached as Exhibit 99.3 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
*
Furnished herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI Vaccines Inc.
|
|
|
|
Date:
June 17, 2019
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff
Baxter
|
|
|
President
and Chief Executive Officer
|
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Sep 2023 to Sep 2024